Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophreniaPaliperidone palmitate dosing guidelines in schizophrenia

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 377-387

  Gopal, S ^a   Gassmann Mayer, C ^a   Palumbo, J ^a   Samtani, M N ^a   Shiwach, R ^b   Alphs, L ^a  

^a JOHNSON AND JOHNSON   (United States)

^b Ortho McNeil Janssen Scientific Affairs LLC ^*

Author keywords

Dosing; Long acting injectable; Paliperidone palmitate; Schizophrenia; Switching

Indexed keywords

NEUROLEPTIC AGENT; PALIPERIDONE; PALIPERIDONE PALMITATE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AGITATION; ANXIETY; BODY MASS; CLINICAL TRIAL; CREATININE CLEARANCE; DELTOID MUSCLE; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUTEUS MAXIMUS MUSCLE; GROUPS BY AGE; HUMAN; INSOMNIA; KIDNEY DISEASE; LIVER DISEASE; MAINTENANCE THERAPY; NEEDLE; NOTE; PSYCHOSIS; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HEALTH PLANNING GUIDELINES; HUMANS; ISOXAZOLES; MAXIMUM TOLERATED DOSE; MODELS, BIOLOGICAL; PALMITATES; PYRIMIDINES; SCHIZOPHRENIA; WITHHOLDING TREATMENT;

EID: 74549136762     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903482772     Document Type: Note

References (38)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl. 4):1-63
2. Andreasen NC. Signs, symptoms and diagnosis of schizophrenia. Lancet 1995;346:477-481
3. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-1315
4. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-267
5. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-1370
6. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliper-idone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-161 (Pubitemid 46178537)
7. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-130 (Pubitemid 46817944)
8. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009;48:585-600
9. Paliperidone palmitate Prescribing Information 2009. Available at: http:// www.invegasustenna.com/invegasustenna/shared/pi/invegasustenna.pdf. Accessed November 2009
10. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approvals and labeling decisions: survey of 42 new drug applications. AAPS J 2005;7:E503-E512
11. Bhattaram VA, Bonapace C, Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007;81:213-221
12. Tornoe CW, Bhattaram V, Earp JC, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 65 NDAs Between 2006 and 2008. American Conference on Pharmacometrics, Mashantucket, CT, USA, Oct 4-7 2009. Poster no. S1
13. Megens AA, Awouters FHL. In vivo pharmacological profile of 9-hydroxyris-peridone the major metabolite of the novel antipsychotic risperidone. Drug Dev Res 1994;33:399-412
14. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73
15. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-779
16. Thyssen, A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Human Psychopharmacol 2009;24:532-539
17. Nasrallah HA, Gopal S, Quiroz J, et al. Efficacy and safety of 3 doses of paliperidone palmitate, an investigational long-acting injectable antipsychotic, in schizophrenia. Biol Psychiatry 2008;63:1S-319S
18. Kramer M, Litman R, Lane R, et al. Efficacy and tolerability of two fixed dosages of paliperidone palmitate in the treatment of schizophrenia: results of a 9-week placebo-controlled trial. Biol Psychiatry 2008;63:1S-319S
19. Gopal S, Lindenmayer JP, Hough D, et al. Safety and tolerability of paliper-idone palmitate injected in the deltoid or gluteus muscle in patients with schizophrenia. Biol Psychiatry 2008;63:1S-319S
20. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022-1033
21. Pandina G, Lindenmayer JO, Lull J. A randomized, double-blind, placebo-controlled, dose-response study to assess efficacy and safety of paliperidone palmitate in adult subjects with schizophrenia. Annual Meeting of the International Congress of Schizophrenia Research, San Diego, CA, USA, March 28-April 2009. Poster no. 31
22. Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001;62:855-859
23. Samtani MN, Kern-Sliwa J, Haskins JT. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, FL, USA, April 19-22, 2009. Poster no. 19
24. Samtani MN, Kern-Sliwa J, Haskins JT, et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. Annual Meeting of the American Psychiatric Association, San Francisco, CA, USA, May 16-21 2009. Poster no. NRI-046
25. Samtani MN, Haskins JT, Alphs S, et al. Maintenance dosing of once-monthly (4-weekly) paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on population simulations. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, FL, USA, 19-22 April 2009. Poster no. 21
26. Samtani MN, Gopal S, Kern Sliwa J, et al. Switching to paliperidone palmitate from other antipsychotics: guidance based on pharmacokinetic modeling and simulations. New Clinical Drug Evaluation Unit, Hollywood, FL, USA, Jun 29-Jul 2 2009. Poster no. I-68
27. Samtani MN, Gopal S, Kern Sliwa J, et al. Management of missed paliperidone palmitate doses based on pharmacokinetic modeling and simulation. New Clinical Drug Evaluation Unit, Hollywood, FL, USA, 29 Jun-2 Jul 2009. Poster no. II-62
28. Fleischhacker WW, Gopal S, Samtani MN, et al. Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: results of two randomized double-blind studies and population pharma-cokinetic simulations. Annual Meeting of the American College of Neuropsychopharmacology, Scottsdale, AZ, USA, Dec 7-11 2008. Poster no. 21
29. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone ER in healthy subjects. Schizophrenia Res 2006;81(Suppl. 1):85-86
30. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-950
31. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235
32. Nyberg S, Nordstrom AL, Halldin C, et al. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 1995;10(Suppl. 3):81-85
33. Kane J, Aguglia E, Altamura, AC, et al. Guidelines for depot antipsychotic treatment for schizophrenia. European Neuropsychopharmacology 1998; 8:55-66
34. Samtani MN, Haskins JT, Alphs L, et al. Maintenance dosing of once-monthly (4-weekly) paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on population simulations. Annual Meeting of the American Psychiatric Association 2009: San Francisco, CA, USA, May 16-21, 2009. Poster no. NRI-036
35. Cirincione B, Redman M, Fielder-Kelley J, et al. Population pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophrenia. Clin Pharmacol Ther 2007;81:S19
36. Cleton A, Rossenu S, Hough D, et al. Assessment of the dose proportionality of paliperidone palmitate, a long-acting injectable antipsychotic, following deltoid or gluteal administration. Annual Meeting of the Institute of Psychiatric Services, Chicago, IL, USA, October 2-5, 2008. Poster no. 59
37. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the advisory committee on immunization practices. MMWR 2006;55(No.):16
38. Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA 1997;277:1709-1711